<H1>Chapter DOI: 10.1208/aapsj070352<br/>Cited-By Count: 33</H1><table border="1" width="30%"><tr><td>Total References</td><td>26</td></tr><tr><td>Springer references</td><td>0</td></tr><tr><td>Non Springer references</td><td>26</td></tr><tr><td>BibStructured Count</td><td width="10%">24</td></tr><tr><td>BibUnstructured Count</td><td width="10%">2</td></tr><tr><td>DOI already available in SpringerLink</td><td>23</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>0</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>0</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>0</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr><tr><td>Valid DOI Enriched</td><td>0</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1</td><td>BibArticle</td><td>Bays HB, McKenney JM, Dujovne CA, et al. Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol.<Emphasis Type="Italic">Am J Cardiol</Emphasis>. 2003;92:538&#8211;543.</td><td><a href=http://dx.doi.org/10.1016/S0002-9149(03)00721-5>10.1016/S0002-9149(03)00721-5</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2</td><td>BibArticle</td><td>Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel Ill guidelines.<Emphasis Type="Italic">Circulation</Emphasis>. 2004;110:227&#8211;239.</td><td><a href=http://dx.doi.org/10.1161/01.CIR.0000133317.49796.0E>10.1161/01.CIR.0000133317.49796.0E</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR3</td><td>BibArticle</td><td>Normand S-L. Meta-analysis: formulating, evaluating, combining, and reporting.<Emphasis Type="Italic">Stat Med</Emphasis>. 1999;18:321&#8211;359.</td><td><a href=http://dx.doi.org/10.1002/(SICI)1097-0258(19990215)18:3&lt;321::AID-SIM28&gt;3.0.CO;2-P>10.1002/(SICI)1097-0258(19990215)18:3&lt;321::AID-SIM28&gt;3.0.CO;2-P</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR4</td><td>BibArticle</td><td>Berry DA, Berry SM, McKellar J, Pearson TA. Comparison of the dose-response relationships of 2 lipid-lowering agents: a Bayesian meta-analysis.<Emphasis Type="Italic">Am Heart J</Emphasis>. 2003;145:1036&#8211;1045.</td><td><a href=http://dx.doi.org/10.1016/S0002-8703(03)00106-6>10.1016/S0002-8703(03)00106-6</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR5</td><td>BibArticle</td><td>Mandema JW, Cox E, Alderman J. Therapeutic benefit of Eletriptan compared to Sumatriptan for the acute relief of migraine pain&#8212;results of a model-based meta-analysis that accounts for encapsulation.<Emphasis Type="Italic">Cephalalgia</Emphasis>. 2005;25:715&#8211;725.</td><td><a href=http://dx.doi.org/10.1111/j.1468-2982.2004.00939.x>10.1111/j.1468-2982.2004.00939.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR6</td><td>BibArticle</td><td>Nawrocki JW, Weiss SR, Davidson MH, et al. Reductions of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor.<Emphasis Type="Italic">Arterioscler Thromb Vasc Biol</Emphasis>. 1995;15:678&#8211;682.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR7</td><td>BibUnstructured</td><td>U.S. Food and Drug Administration, <span style='background:#66FF66'>2002</span>. <span style='background:#FFFF0F'>NDA 21-445. Zetia (ezetimibe) Medical Reviews. CDER, FDA</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR8</td><td>BibArticle</td><td>Davidson M, McKenney J, Stein E, et al. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I.<Emphasis Type="Italic">Am J Cardiol</Emphasis>. 1997;79:1475&#8211;1481.</td><td><a href=http://dx.doi.org/10.1016/S0002-9149(97)00174-4>10.1016/S0002-9149(97)00174-4</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR9</td><td>BibArticle</td><td>Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (The CURVES Study).<Emphasis Type="Italic">Am J Cardiol</Emphasis>. 1998;81:582&#8211;587.</td><td><a href=http://dx.doi.org/10.1016/S0002-9149(97)00965-X>10.1016/S0002-9149(97)00965-X</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR10</td><td>BibUnstructured</td><td>U.S. Food and Drug Administration, <span style='background:#66FF66'>1996</span>. <span style='background:#FFFF0F'>NDA 20-702. Lipitor (atorvastatin) Medical Reviews. CDER, FDA</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR11</td><td>BibArticle</td><td>Olsson AG, Pears J, McKellar J, Mizan J, Raza A. Effect of Rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia.<Emphasis Type="Italic">Am J Cardiol</Emphasis>. 2001;88:504&#8211;508.</td><td><a href=http://dx.doi.org/10.1016/S0002-9149(01)01727-1>10.1016/S0002-9149(01)01727-1</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR12</td><td>BibArticle</td><td>Paoletti R, Fahmy M, Mahla G, Mizan J, Southworth H. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with Pravastatin and Sim vastatin in hypercholesterolaemic patients: a randomized, double-blind study.<Emphasis Type="Italic">J Cardiovasc Risk</Emphasis>. 2001;8:383&#8211;390.</td><td><a href=http://dx.doi.org/10.1097/00043798-200112000-00008>10.1097/00043798-200112000-00008</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR13</td><td>BibArticle</td><td>Bays HE, Moore PB, Drehobl MA, et al. Effectiveness and tolerability of Ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies.<Emphasis Type="Italic">Clin Ther</Emphasis>. 2001;23:1209&#8211;1230.</td><td><a href=http://dx.doi.org/10.1016/S0149-2918(01)80102-8>10.1016/S0149-2918(01)80102-8</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR14</td><td>BibArticle</td><td>Davidson M, Ma P, Stein EA, et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with Rosuvastatin versus Atorvastatin in patients with type IIa or IIb hypercholesterolemia.<Emphasis Type="Italic">Am J Cardiol</Emphasis>. 2002;89:268&#8211;275.</td><td><a href=http://dx.doi.org/10.1016/S0002-9149(01)02226-3>10.1016/S0002-9149(01)02226-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR15</td><td>BibArticle</td><td>Blasetto JW, Stein EA, Brown WV, Chitra R, Raza A. Efficacy of Rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups.<Emphasis Type="Italic">Am J Cardiol</Emphasis>. 2003;91:3&#8211;10.</td><td><a href=http://dx.doi.org/10.1016/S0002-9149(03)00003-1>10.1016/S0002-9149(03)00003-1</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR16</td><td>BibArticle</td><td>Olsson AG, Istad H, Luurila O, et al. Effects of Rosuvastatin and Atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia.<Emphasis Type="Italic">Am Heart J.</Emphasis>. 2002;144:1044&#8211;1051.</td><td><a href=http://dx.doi.org/10.1067/mhj.2002.128049>10.1067/mhj.2002.128049</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR17</td><td>BibArticle</td><td>Brown WV, Bays HE, Hassman DR, et al. Efficacy and safety of Rosuvastatin compared with Pravastatin and Simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial.<Emphasis Type="Italic">Am Heart J.</Emphasis>. 2002;144:1036&#8211;1043.</td><td><a href=http://dx.doi.org/10.1067/mhj.2002.129312>10.1067/mhj.2002.129312</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR18</td><td>BibArticle</td><td>Dujovne CA, Ettinger MP, McNeer JF, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, Ezetimibe, in patients with primary hypercholesterolemia.<Emphasis Type="Italic">Am J Cardiol</Emphasis>. 2002;90:1092&#8211;1097.</td><td><a href=http://dx.doi.org/10.1016/S0002-9149(02)02798-4>10.1016/S0002-9149(02)02798-4</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR19</td><td>BibArticle</td><td>Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with Simvastatin in patients with primary hypercholesterolemia.<Emphasis Type="Italic">J Am Coll Cardiol</Emphasis>. 2002;40:2125&#8211;2134.</td><td><a href=http://dx.doi.org/10.1016/S0735-1097(02)02610-4>10.1016/S0735-1097(02)02610-4</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR20</td><td>BibArticle</td><td>Schneck DW, Knopp RH, Ballantyne CM, McPherson R, Chitra RR, Simonson SG. Comparative effects of Rosuvastatin and Atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease.<Emphasis Type="Italic">Am J Cardiol</Emphasis>. 2003;91:33&#8211;41.</td><td><a href=http://dx.doi.org/10.1016/S0002-9149(02)02994-6>10.1016/S0002-9149(02)02994-6</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR21</td><td>BibArticle</td><td>Knopp RH, Gitter H, Truitt T, et al. Effects of Ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia.<Emphasis Type="Italic">Eur Heart J.</Emphasis>. 2003;24:729&#8211;741.</td><td><a href=http://dx.doi.org/10.1016/S0195-668X(02)00807-2>10.1016/S0195-668X(02)00807-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR22</td><td>BibArticle</td><td>Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of Ezetimibe coadministered with Atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.<Emphasis Type="Italic">Circulation</Emphasis>. 2003;107:2409&#8211;2415.</td><td><a href=http://dx.doi.org/10.1161/01.CIR.0000068312.21969.C8>10.1161/01.CIR.0000068312.21969.C8</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR23</td><td>BibArticle</td><td>Melani L, Mills R, Hassman D, et al. Efficacy and safety of Ezetimibe coadministered with Pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.<Emphasis Type="Italic">Eur Heart J</Emphasis>. 2003;24:717&#8211;728.</td><td><a href=http://dx.doi.org/10.1016/S0195-668X(02)00803-5>10.1016/S0195-668X(02)00803-5</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR24</td><td>BibArticle</td><td>Kerzner B, Corbelli J, Sharp S, et al. Efficacy and safety of Ezetimibe coadministered with Lovastatin in primary hypercholesterolemia.<Emphasis Type="Italic">Am J Cardiol</Emphasis>. 2003;91:418&#8211;424.</td><td><a href=http://dx.doi.org/10.1016/S0002-9149(02)03236-8>10.1016/S0002-9149(02)03236-8</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR25</td><td>BibArticle</td><td>Illingworth DR, Erkelens DW, Keller U, Thompson GR, Tikkanen MJ. Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin.<Emphasis Type="Italic">Lancet</Emphasis>. 1994;343:1554&#8211;1556.</td><td><a href=http://dx.doi.org/10.1016/S0140-6736(94)92945-9>10.1016/S0140-6736(94)92945-9</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR26</td><td>BibArticle</td><td>Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis.<Emphasis Type="Italic">BMJ</Emphasis>. 2003;326:1423&#8211;1430.</td><td><a href=http://dx.doi.org/10.1136/bmj.326.7404.1423>10.1136/bmj.326.7404.1423</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr></table>